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Abstract
Background: The influence of the tumor microenvironment and tumor-stromal interactions on the heterogeneity
of response within breast cancer subtypes have just begun to be explored. This study focuses on patients with
estrogen receptor-positive/human epidermal growth factor receptor 2-positive (ER+/HER2+) breast cancer receiving
neoadjuvant chemotherapy and HER2-targeted therapy (NAC+H), and was designed to identify novel predictive
biomarkers by combining gene expression analysis and immunohistochemistry with pathologic response.
Methods: We performed gene expression profiling on pre-NAC+H tumor samples from responding (no or minimal
residual disease at surgery) and non-responding patients. Gene set enrichment analysis identified potentially relevant
pathways, and immunohistochemical staining of pre-treatment biopsies was used to measure protein levels of those
pathways, which were correlated with pathologic response in both univariate and multivariate analysis.
Results: Increased expression of genes encoding for stromal collagens, including Col10A1, and reduced expression of
immune-associated genes, reflecting lower levels of total tumor-infiltrating lymphocytes (TILs), were strongly associated
with poor pathologic response. Lower TILs in tumor biopsies correlated with reduced likelihood of achieving an
optimal pathologic response, but increased expression of the Col10A1 gene product, colXα1, had greater predictive
value than stromal abundance for poor response (OR = 18.9, p = 0.003), and the combination of increased colXα1
expression and low TILs was significantly associated with poor response in multivariate analysis. ROC analysis suggests
strong specificity and sensitivity for this combination in predicting treatment response.
Conclusions: Increased expression of stromal colXα1 and low TILs correlate with poor pathologic response in
ER+/HER2+ breast tumors. Further studies are needed to confirm their predictive value and impact on long-term
outcomes, and to determine whether this collagen exerts a protective effect on the cancer cells or simply reflects other
factors within the tumor microenvironment.
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Background
Breast cancer treatment is largely determined by hormone
receptor and human epidermal growth factor receptor-2
(HER2) expression, but there is significant variability of re-
sponse and prognosis within the subtypes defined by these
markers. Being able to identify characteristics or markers
on pretreatment samples that predict a higher likelihood
of treatment-refractory disease could spare patients from
exposure to ineffective and often toxic therapies, and pro-
mote the development of novel treatments that target and
neutralize these factors.
In the past, most analyses have focused on identifying
markers expressed by the tumor cells themselves. Tumor
biopsies and surgical specimens consist of a mixture of
cancer cells and surrounding stroma comprised of a var-
iety of cell types, and while the traditional approach to
tumor biology disregarded the impact that those other
tissues might have on tumor behavior, more recently
there has been an increased appreciation of the possibil-
ity that the tumor microenvironment and tumor-stromal
interactions could play an important role in determining
response. These include the abundance and character of
tumor-infiltrating lymphocytes (TILs) and levels of expres-
sion of proteins such as PD-L1 that can modify immune
response to the growing tumor, both of which may have a
significant impact on prognosis, especially in more aggres-
sive breast cancer subtypes [1, 2].
Response rates to NAC vary widely depending on sub-
type in breast cancer. In HER2+ patients, the addition of
the HER2-targeting monoclonal antibody trastuzumab
to standard NAC has been shown to improve not only the
pathological Complete Response (pCR) rate in the NAC
setting, but also recurrence-free and overall survival in
the adjuvant setting [3]. However, despite the addition
of trastuzumab or even dual HER2-targeting therapies
with trastuzumab and either lapatinib or pertuzumab
to NAC (NAC+H), a significant percentage of HER2+ pa-
tients do not achieve a pCR or minimal residual disease.
In the TRYPHAENA trial, the pCR for ER-/HER2+ is
77 % but only 48 % for ER+/Her2+ with cases from all
three arms combined [4]. In NeoSphere trials, few patho-
logic complete responses were noted in tumors that are
hormonal receptor positive in all four arms [5]. There was
a significant difference in pCR rates between hormone
positive and negative tumors; the pCR was 40 % for ER-
groups and only 17 % for ER+ groups. This discrepancy
may reflect differences in cancer cell biology, related to
proliferation or dependence on HER2-mediated signaling;
it is also possible that differences in the microenvironment
mediate response. At this time, there is no reliable,
validated method to distinguish responders from non-
responders. Thus, many patients are needlessly treated
with toxic chemotherapy with uncertain benefit from the
treatment. The aim of this work was to examine gene
expression profiles of tumors at the time of the pre-
treatment biopsy to identify molecular features that may
be associated with chemoresponse. Such markers of NAC
response could be useful to reduce chemotherapy-reduced
morbidity, and identify new therapeutic approaches to
treat ER+/HER2+ breast cancer.
In this study, we chose to focus on the ER+/HER2+
subtype where patients do not respond well to NAC and
suffer from overall survival rates comparable to TNBC.
The cross-talk between these oncogenic pathways drives
cross-resistance to current therapies, leading to the use
of cytotoxic chemotherapy to treat this subtype [6]. We
hypothesize that new predictive markers could be devel-
oped by identifying candidate genes and pathways from
gene expression profiling followed by detailed analysis of
candidate markers using immunohistochemistry [7, 8].
We found that collagens, in particular the expression of
the protein product from the ColXA1 gene, were strongly
associated with NAC response in ER+/HER2+ breast tu-
mors. The presence of collagen in the surrounding tumor
milieu has long been known to influence cancer cells.
Collagens can induce epithelial-mesenchymal transi-
tions and related invasive properties of breast cancer
cells [9]. However, the utility of any specific collagen as
a prognostic marker remains unclear. Expression of
ColXA1 has been included in published stromal expres-
sion signatures [10, 11], but the expression of ColXA1
protein product, colXα1, has not been evaluated. For these
reasons, we examined the potential for the expression of
the colXα1 protein by immunohistochemistry to predict
response to NAC in ER+/HER2+ breast tumors.
Methods
Patients and tissue samples
Selection of patients and analysis was approved by the
Rhode Island Hospital Institutional Review Board, ap-
proval #467617, and the Women and Infants Hospital
Institutional Review Board, #14–0090. Written informed
consent was obtained from each patient for tissue collec-
tion. A retrospective natural language search of the sur-
gical pathology databases was performed to identify all
patients who received NAC. Among patients who received
NAC at the Lifespan Comprehensive Cancer Centers at
Rhode Island Hospital and Miriam Hospital or at Women
and Infants Hospital of Rhode Island between 2007 and
2014, we identified those with ER+/HER2+ cancers who
received NAC+H and for whom sufficient tissue was avail-
able for analysis (Table 1, see Additional file 1: Table S1).
The biopsy samples in some cases were exhausted after
multiple immunohistochemistry and florescent in situ
hybridization studies, which could not be included in this
study. H&E slides of all biopsies were reviewed. We
reviewed histological features such as tumor type, size, ex-
tent of the disease, lymph node status and histological
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grade using the Nottingham combined histologic grading
system. ER/PR/Her2 staining was the data retrieved from
the pathology reports for the purpose of the study. HER2
was considered to be positive if the grade of immunostain-
ing was 3+, or a 2+ result showed gene amplification via
fluorescent in situ hybridization (FISH). In the FISH
analyses, each copy of the HER2 gene and its centromere
17 (CEP17) reference were counted. The interpretation
followed the criteria of the ASCO/CAP guidelines for
HER2 IHC classification for breast cancer: positive if the
HER2/CEP17 ratio was higher than 2.0 [12].
Pathological response to NAC was assessed by the
AJCC cancer staging and residual cancer burden (RCB)
score after 3–6 months of treatment [13]. The RCB sys-
tem stratifies patients with residual invasive cancer by
size and invasive cellularity of the residual tumor bed,
number of involved lymph nodes and largest focus of
cancer in an involved node into classes I, II, and III (RCB
class 0 is synonymous with having achieved a pCR), which
has been shown to correlate with distant breast cancer
recurrence in patient with HER2+ cancers [14]; on-line
Table 1 Association of clinical characteristics to neoadjuvant
treatment response by subtype
Characteristic No. % Good Response P
ER+/HER2+ cases used for Collagen X IHC









Pre-Treatment Lymph Node Status 0.3
Negative 15 47
Positive 35 31












0≤ 10 % 20 15
11≤ 20 % 9 22
21≤ 30 % 5 40
31≤ 40 % 7 42
41≤ 50 % 7 86













Table 1 Association of clinical characteristics to neoadjuvant
treatment response by subtype (Continued)
Age, y
<50 35 51 0.07
≥50 39 31










0≤ 10 % 27 11
11≤ 20 % 15 40
21≤ 30 % 8 37.5
31≤ 40 % 10 60
41≤ 50 % 12 83






P was calculated by Fisher exact test. a Pearson Chi-Square p-value
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calculator available at http://www.mdanderson.org/breast-
cancer_RCB. Patients who achieved a pCR or minimal
residual disease (RCB class 0 and I) were considered good
pathologic responders, while patients with more signifi-
cant residual disease (RCB class II-III) were considered
poor pathologic responders. Cases from 2007, before RCB
guidelines were first were reviewed and RCB scores were
calculated, were based on information from pathology re-
ports. Two of the 74 patients received hormonal therapy.
Five cases receiving chemotherapy of unknown type were
included in this study because the study examined a range
of different neoadjuvant therapies and these patients were
verified to have received chemotherapy (see Additional
file 1: Table S1). The observations are therefore contingent
on receiving neoadjuvant chemotherapy for ER+/HER2+
breast tumors.
Microarray and qPCR analysis
RNA extraction and purification
From the ER+/HER2+ patients we selected a mixture of
good and poor responders for whom we had sufficient
tissue for this assay. Ten micron tumor sections were
scraped from the slides for total RNA extraction. RNA
was purified using the RecoverAll Total Nucleic Acid
Extraction Kits for FFPE tissues (Ambion, Austin, TX)
and further purified and concentrated with the RNEasy
Minelute Cleanup Kit (Qiagen, Valencia, CA).
Expression microarray and qPCR
RNA was isolated and purified using the RNeasy FFPE kit
(Qiagen, Valencia, CA, USA). One hundred nanograms of
total RNA was amplified using Affymetrix’ Sensation Plus
FFPE amplification kit following the manufacturer’s in-
structions and labeled cDNA was hybridized to Affymetrix
(Santa Clara, CA, USA) HTA 2.0 microarrays and visual-
ized at the Brown University Genomics Core Facility
following the manufacturer’s instructions. Signals were
estimated using RMA [15]. Fold change, t-tests, and
multiple hypothesis tests were calculated in R. Data are
available in GEO, GSE67982.
For real-time qPCR, cDNA was prepared using Quanti-
Tect Reverse Transcription Kit (Qiagen). qPCR was per-
formed on a Mx3005p (Agilent) with Brilliant III SYBR
Green (Agilent). Relative expression fold changes were
calculated relative to GAPDH.
Gene expression and pathway analysis
Microarray signals were analyzed for statistical significance
in terms of differences between samples between good
and poor responders. We applied gene set enrichment
analysis (GSEA) to investigate pathways and groups of
genes that may be associated with NAC response, which
identified collagens and immune pathways as strongly
associated with good pathologic response. The collagen
transcript, Col10A1, was one of the top-ranked transcripts
associated with NAC response for which an available com-
mercial antibody was available. Collagen, type 10, alpha 1
(gene name Col10A1 and protein product ColXα1) is a
secreted, homotrimeric short-chain collagen and is up-
regulated in a variety of tumor types with restricted or
undetectable expression in a large spectrum of normal
tissues, normal primary cultures and tumor cell lines
[7, 8]. After verification of the microarray observations
by qPCR, we tested the association of ColXα1 expres-
sion as well as other tumor microenvironmental factors
such as the abundance of tumor associated stroma and
TILs in the pre-treatment biopsy samples to correlate
with post-treatment response. TCGA RNA-seq data for
breast invasive carcinoma were downloaded from the
Firehose Broad GDAC [16]. TCGA clinical data were
downloaded from the TCGA data archive in September
2015 (http://cancergenome.nih.gov/).
Tumor-associated stroma and TIL analysis
We morphologically evaluated the amount intratumoral
stroma and TILs on pre-treated biopsy samples which
commonly consisted of 2–5 needle cores of average
1.5 cm in length obtained with either a 14 gauge spring-
loaded biopsy device or a 12 gauge vacuum-assisted
biopsy device. The amount of intratumoral stroma was
scored as 0 to 2: 0 for absent or minimal stroma
(<10 %), 1 for mild to moderate amount of stroma
(10–40 %) and 2 for abundant stroma (≥40 %). Stromal
and intratumoral TILs (sTILs and iTILs) were evalu-
ated based on criteria published by Denkert et al. [2].
Briefly, iTILs were defined as lymphocytes in direct
contact with the tumor cells, whereas sTILs were de-
fined as lymphocytes in the surrounding stroma, with
the percent of the tumor or stromal volume comprised
of infiltrating lymphocytes, as opposed to tumor or
other stromal tissues, on an H&E stained biopsy sec-
tion estimated by the reading pathologists, with results
reported in increments of 10 (0–1 % was scored as 0,
with all other estimates rounded up to the next high-
est decile - i.e., 11–20 % was scored as 20). sTILs and
iTILs were totaled to calculate TILs. The trends were
similar for each lymphocyte fraction (data not shown).
sTILs were chosen to be analyzed as they were consid-
ered to the most consistent metric as recommended
by the International TILs Working Group [17]. The
histological evaluation was graded independently by two
pathologists (YW and JX), who were blinded to clinical in-
formation including the post-treatment outcome, at the
time of analysis, with the summary score representing the
mean of the two separate scores. The two pathologists
evaluated 30 separate cases (triple negative breast cancer
cases) together to get a general agreement of the sTIL.
The actual study cases were evaluated independently, the
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concordance is about 95 %. The cases with greater than
10 % difference were reviewed together and the average
score was used.
Immunohistochemistry and ColXα1 expression scoring
Four-micron sections were cut from formalin-fixed
paraffin-embedded tissue blocks, heated at 60 °C for
30 min, deparaffinized, rehydrated and subjected to
antigen retrieval by heating the slides in epitope retrieval
buffer in a water bath at 95 °C for 45 min. The slides were
then incubated with either mouse monoclonal antibodies
or rabbit polyclonal antibodies for 30 min at room
temperature in a DAKO Autostainer. Anti- colXα1 (1:50,
eBioscience/Affymetrix, Clone X53), estrogen receptor
(1:50, DAKO (Santa Clara, CA, USA), clone 1D5), proges-
terone receptor (1:400, DAKO, clone 1A6), and HER2/neu
(DAKO HercepTestTM) were used for immunohistochem-
istry. The immunoreactivity was detected using the DAKO
EnVision method according to the manufacturers recom-
mended protocol. Peri- and intra-tumoral stromal staining
for ColXα1 was scored as 0, 1+, 2+, and 3+. Briefly, 0 as no
staining; 1+ as weak staining; 2+ as <10 % of stroma tissue
with intense staining present; 3+ as >10 % of stroma tissue
with patchy intense staining. All scoring was performed
blinded to the outcome and many cases were scored before
the outcome data was available.
Statistical analysis
SPSS v22 for MacOS (SPSS, Chicago, IL, USA) was used
for all statistical analysis. P < 0.05 was considered statisti-
cally significant. All p-values reported are two-sided. For
the logistic regression, all factors were analyzed as con-
tinuous variables.
Results
Patients and clinical information
Among 538 patients who received NAC at the partici-
pating hospital, we identified 74 ER+/HER2+ patients
for whom we had pathologic response data and suffi-
cient pretreatment tissue for analysis (Fig. 1). Their
clinical and pathologic data are summarized in Table 1;
92 % (68 of 74) were clinical stage ≥ IIB. Most received
either doxorubicin and cyclophosphamide followed by
paclitaxel and trastuzumab (n = 33) or docetaxel, car-
boplatin and trastuzumab (n = 35). The addition of
pertuzumab to the neoadjuvant regimen for HER2+
cancer had not yet been routinely adopted. 19 % (14 of
74) of patients achieved a complete pCR (RCB class
0), and 40.54 % (30 of 74) had a good pathologic re-
sponse (RCB class 0 or I). There were no significant
statistical differences in the post-treatment response be-
tween patients who received TCH vs. AC-TH treatment
options.
Fig. 1 Flow diagram of the approach to identify and test Col10A1 in ER+/HER2+ breast tumors. From 538 patients, 74 ER+/HER2+ breast tumors
were selected for analysis. 11 ER+/HER2+ tumors were selected for expression profiling using Affymetrix HTA 2.0 microarrays. After qPCR
verification, we evaluated the level of colXα1 protein in primary tumors before NAC using immunohistochemistry to test the expression of colXα1
protein levels in 50 ER+/HER2+ breast tumors with available tissue
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Association of Col10A1 mRNA and NAC response in
ER+/HER2+ cancer
In order to identify novel markers for NAC response in
this subtype, we randomly selected 5 tumors sampled
from patients who achieved good response (RCB 0 or I)
with NAC+H and 6 from patients who did not achieve a
good response (RCB II or III) for genome-wide expres-
sion profiling using Affymetrix HTA 2.0 microarrays
(Fig. 1). We hypothesized that even with a small set of
cases, candidate markers strongly associated with pCR
would be detected. Only 30 transcripts were significantly
differentially expressed (Fc >2, p < 0.05) including three
collagens (subtypes Col10A1, Col14A1, and Col3A1),
which were up-regulated in tumors that had poor
response (see Additional file 2: Table S2). Other differ-
entially expressed genes associated with more aggres-
sive breast cancer including ERBB4 and TGFB3 are
up-regulated in poor responders in these data. How-
ever, qPCR analysis of TGFB3 in 42 tumors did not
find a strong association with response [18]. Likely
because of the small number of significantly differen-
tially expressed transcripts, no transcripts had a cor-
rected p < 0.05 after multiple hypothesis correction.
Because so few genes were considered significantly
differentially expressed, representative significantly
differentially expressed genes were verified by qPCR
(see Additional file 3: Figure S1).
We performed pathway analysis to identify groups of
genes associated with good response. Gene Set Enrichment
Analysis (GSEA) identified many pathways significantly
biased towards either good responders or resistant tumors
(see Additional file 4: Table S3). In ER+/HER2+ tumors,
within the Gene Ontology gene sets, increased expression
of immune pathways, and components of the cell cycle
were associated with pCR, while drug metabolism, RNA
metabolism, and expression of certain collagens were asso-
ciated with poor responding tumors (see Additional file 4:
Table S3).
We aimed to identify a representative transcript of a
pathway or group of transcripts that we could test by
IHC in an extended cohort of tumors. The collagen
Gene Ontology gene set is strongly biased towards poor
responding tumors (NES = −1.9, FDR = 0.009) (Fig. 2)
and three transcripts encoding collagens (Col10A1,
Col14A1, and COL3A1) were among the most signifi-
cant differentially expressed genes (see Additional file 4:
Table S3).
To validate the microarray observations, we per-
formed qPCR on five transcripts, significantly differentially
expressed (Fc > 2, p < 0.05) between responding and non-
responding tumors among those analyzed by microarrays
and found good overall correlation (R = 0.69, P <0.001),
(See Additional file 3), including the Col10A1 transcript
(Fig. 2d).
Total tumor-infiltrating lymphocytes and tumor-
associated stroma are associated with good response
in ER+/HER2+ tumors
The gene expression data (Additional file 2: Table S2
and Additional file 4: Table S3) suggested that higher
levels of lymphocytes were associated with achieving a
good response. This is highlighted by increased expres-
sion of CXCL10 (Fc 1.8, p = 0.01) and IL7R, highly
ranked by GSEA, in responsive tumors. These gene
expression data predicted that examination of infiltrating
lymphocytes is warranted and that such TILs would be
associated with achieving good response.
To test the gene expression observations, we examined
each tumor for the number of TILs. TILs have been
proposed as a predictor of pCR in TNBC [19]. However,
the association between TILs and good responders in
ER+/HER2+ tumors remains uncertain. We found that
higher levels of TILs corresponded to tumors with good
responders in the full 74 ER+/HER2+ patient cohort
(Table 1). In univariate analysis using a logistic
regression model, TILs were found to be predictive for
good response (OR = 0.94, P = 0.001) (Table 2), and the
association with good response was observed for both
tumor-associated stroma and TILs (Table 1 and
Additional file 5: Table S4).
ColXα1 expression predicts response to NAC in
ER+/HER2+ cancer
Col10A1 was the most significantly biased collagen in
the GSEA analysis (Fig. 2c). COL10A1 has been included
in stromal expression signatures in breast cancer [10].
Therefore, the protein product of the Col10A1 gene,
colXα1 was a strong candidate to predict NAC response
in ER+/HER2+ breast tumors and warranted further
evaluation at the protein level based on the literature
and these gene expression data.
To evaluate the findings from the gene expression data
that collagens are significantly associated with pCR, we
tested the usefulness of an anti-colXα1 monoclonal anti-
body to predict poor response and evaluated its relation-
ship with other microenvironment metrics including the
amount of tumor-associated stroma and TILs for its role
in pCR. We performed IHC in 10 reduction mammo-
plasty cases to define the colXα1 expression pattern in
normal breast tissue. In normal breast tissue, stain was
negative for colXα1 except for occasional faint staining
in a perivascular distribution pattern (data not shown).
Among the 74 ER+/HER2+ cases in our study group, 50
pre-treatment needle biopsy samples had sufficient re-
sidual material (at least 1 cm tumor/stroma in a 12 gauge
needle core) to allow evaluation with anti- colXα1 IHC.
The overall response rate (pCR + RCB I) in this set was
36 % (18 of 50 patients) Table 1. Microenvironmental
factors including decreased amount of stroma (P = 0.016)
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and higher levels of TIL (P < 0.001) were associated with
good response in these 50 cases (Table 1). In tumor sam-
ples, immunostaining of colXα1 was observed as intense
peri- and intra-tumoral distribution in some tumors in the
RCBIII case (Also see 20× image in Additional file 6:
Figure S2). A periductal/perivascular colXα1 staining
pattern was frequently observed (Fig. 3). Increased colXα1
staining was strongly associated with a poor response by a
chi-squared test (P < 0.001) (Table 1). The two cases with
no stroma were scored as having negative colXα1 staining
as no signal was observed.
ColXα1 predicts NAC response in ER+/HER2+ cancer
independently
We performed univariate and multivariate analyses using
a logistic regression model in order to assess the associa-
tions between response, TILs, colXα1 IHC and other
established clinicopathological parameters. Univariate
Table 2 Odds of response after neoadjuvant chemotherapy
from logistic regression model. N = 50
Characteristic OR (95 % CI) P
Univariate
Age 5.6 (1.6–20.0) 0.008
sTIL 0.46 (0.29–0.72) 0.001
Stroma 6.6 (1.9–23.4) 0.003
colXα1 18.9 (2.8–129) 0.003
Multivariate
Age 0.23 (0.009–5.9) 0.37
sTIL 0.39 (0.16–0.92) 0.03
Stroma 1.9 (0.17–22) 0.6
colXα1 28 (1.6–487) 0.022
Fig. 2 Association of colXα1 expression with NAC response. a Box plot of the Col10A1 probeset on the Affymetrix HTA 2.0 microarray distinguishes
good and poor responding ER+/HER2+ breast tumors. The one outlier on the array, has an intermediate colXα1 IHC score of 1. b Gene Set Enrichment
Analysis reveals enrichment of the Gene Ontology (GO) category, collagens, in pCR resistant ER+/HER2+ breast tumors. Each black line represents one
gene in the GO collagen gene set. c Heat map of mRNA expression changes for all measured collagens on the microarray. d qPCR of Col10A1 mRNA
expression correlates with the microarray data
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analysis showed that high levels of colXα1 measured by
IHC were associated with patients not achieving pCR or
RCB I (OR = 18.88, P = 0.003) (Table 2). No patients with
tumors with colXα1 scores of 2 or 3 achieved pCR or
RCB I. More abundant stroma (OR = 6.92, P = 0.003)
and positive lymph nodes (OR = 12.3, P = 0.003) were
also associated with patients not achieving pCR or RCB
I. In contrast, higher levels of TIL were associated with
patients achieving good response (OR = 0.94, P = 0.001).
Because the modest size of this study, multivariate ana-
lysis was performed comparing two variables at a time
to avoid overfitting (Table 2).
Multiple lines of evidence suggest that colXα1 IHC is
a strong candidate marker. ColXα1 IHC discriminates
good from poor responding patients with a low false
positive rate. This is also reflected in the ROC curves
where the colXα1 IHC is a more specific and sensitive
marker of good response compared to stroma (Fig. 4a).
ROC curves and box plots demonstrate that colXα1 and
TIL strongly separate patients by good response, while
the stroma score did not (Fig. 4). This indicated that
high colXα1 expression by itself is an independent pre-
dictive factor, and not merely a reflection of more tumor
associated stroma. Clinical biomarkers need to have very
Fig. 3 Immunohistochemistry of colXα1. a Representative colXα1 immunostaining in low- and high- colXα1 expressing ER+/HER2+ breast
cancers. Two representative cases, one with no response, RCBIII, and strong colXα1 signal, score = 2, and one with good response, RCB0, and no
colXα1 signal, score = 0, are shown. Arrows indicate regions with tumor cells. b RNA levels as determined by the microarray correlate with colXα1
IHC signal in 9 cases
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high specificity and sensitivity [20]. The high sensitivity,
specificity, and accuracy of the colXα1 scoring support
its further development as a marker for response in the
NAC setting.
To assess how colXα1 may be inducing chemoresistance,
we evaluated the genes correlated with ColXA1 mRNA
expression. Pathways associated with increased metabolism,
chemoresistance and oncogenicity are strongly correlated
with ColXA1 expression (see Additional file 5: Table S4).
GSEA analysis of the ranked list of ColXA1 correlated
genes revealed that the Epithelial-Mesenchymal Transition
(EMT) hallmark gene set was strongly enriched (Fig. 5).
Collagens are reported to help drive the mesenchymal state
in tumors [21]. To further test the potential connection
between ColXA1 and EMT we evaluated the co-expression
in 123 TCGA invasive ER+/HER2+ breast tumors with
RNA-seq expression data. Collagen positively correlated
transcripts include EMT enrichment including the EMT
transcription factor, SNAI2, GPX8, thought to help protect
cells from oxidative damage, other collagens (Col12A1 and
Col11A1) and collagen binding proteins including fibro-
nectin, suggesting a broad network of a ColXA1 based
network (see Additional file 5: Table S4). Collagens are
known to increase matrix stiffness, which can induce
EMT [22]. Other pathways enriched in highly correlated
Col10A1 genes include TGFB signaling (TGFB3 and
MAPK3). These findings support a connection between
the expression of colXa1, EMT, the expression of putative
resistance mechanisms, and response in the neoadjuvant
setting.
Discussion
The diversity of breast carcinoma is increasingly reflected
in the spectrum of therapeutic approaches that are based
on known biomarkers. ER, PR and HER2 are routinely
used in clinical practice as a guide for the selection of ther-
apy for breast cancer patients. In patients with stage II-III
breast cancer, achievement of pCR to neoadjuvant chemo-
therapy correlates with improved long-term outcomes,
however the predictive value of the standard clinical bio-
markers such as ER, PR and HER2 is limited, motivating
this study to identify factors mediating response. We de-
fined the subtype of breast cancer by treatment protocols,
and not the molecular markers used to define luminal vs.
basal tumors [23]. We focused on the ER+/HER2+ sub-
type where less than 50 % of tumors respond to NAC
(Table 1), despite combining HER2 targeted therapy, tras-
tuzumab, with taxane and platinum based chemotherapy.
To identify new markers, we combined RNA expression
profiling with IHC to discover the importance of colXα1
positive stroma. Here, we found that collagens, namely
colXα1, are up-regulated in breast tumors that do not
respond to therapy in the ER+/HER2+ subtype. We
observed an association at the mRNA level by qPCR and
microarray and evaluated 50 cases at the protein level by
IHC. Together, these RNA and protein data support the
Fig. 4 ColXα1 IHC scoring is strongly associated with NAC response. a ROC analysis of colXα1 IHC scores, stroma scores, and percent TIL.
AUC = Area Under the Curve, SE = Standard Error. b Stroma and sTIL scores did not distinguish responders as strongly as colXα1 IHC. Box
and whisker plots of each parameter show distinct separation between tumors that responded to NAC and those that with no response.
*P < 0.05, ***P < 0.001
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conclusion that colXα1 expression is strongly associated
with chemotherapy response. We decided to focus on the
role of collagens as collagens have been reported in gene
expression signatures associated with response in the
NAC setting and survival in the adjuvant setting. To our
knowledge, this is the first study to evaluate the expression
of colXα1 protein in breast tumors.
ColXα1 expression levels in the stroma of ER+/HER2+
tumors have a bimodal distribution, an important
characteristic for a biomarker. While some ER+/HER2+
tumors do not express colXα1, those ER+/HER2+ tumors
with strong expression (IHC score of 2 or 3) all were re-
sistant to treatment. Thus, in this cohort, colXα1 predicts
no false positives, and just 8 false negatives (Table 1).
The importance of the tumor microenvironment in in-
fluencing chemosensitivity is becoming increasingly clear
[23]. The amount of stroma has been associated with
chemosensitivity in many studies [24, 25]. Various stro-
mal markers including tenascin, fibronectin and collagen
type IV have been correlated with more aggressive be-
havior in breast cancer [26]. Although the quantity of
stroma is correlated with pCR in this study, it is also
clear that there are different types of stroma [27]. A variety
of collagens are highly expressed in breast tumors contrib-
uting to its dense structure [9]. Collagens have long been
known to be critical players in the extracellular matrix of
breast tumors [9, 27], including mediating drug resistance
[28], and alignment of collagens has been proposed to
indicate progression in breast tumors [29, 30]. Collagen
alignment was reported to correlate with expression of
syndecan-1, but this gene was not significantly differentially
expressed in this study (Fc = 0.15). However, there are lim-
ited data on the expression and function of many specific
collagen subtypes by IHC in breast cancer patients.
Fig. 5 Col10A1 expression is correlated with epithelial-mesenchymal transition gene sets. GSEA reveals the Epithelial-Mesenchymal Transition Hallmark
gene set is strongly enriched in Col10A1 positively correlated genes in both the RIH dataset and in 123 TCGA ER+/HER2+ breast tumors
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Collagen is associated with the major ECM transformations
and the collagen subtype COLl11A1 has been associated
with metastasis and disease progression in breast cancer
[9]. In this study, COL3A1 and COL14A1 are among
the most significantly differentially expressed tran-
scripts (see Additional file 4: Table S3) and are good candi-
dates for further evaluation, as they are not one of the
dominant forms of collagen in normal breast tissue. Further
studies are warranted to test which collagens, and if a com-
bination of specific collagens are good predictors of re-
sponse at the RNA and protein levels.
Col10A1 mRNA expression is up-regulated in a variety
of human malignancies compared to normal tissue, includ-
ing breast tumors [8]. Increased expression of Col10A1 has
been a part of breast cancer signatures, including a CD10+
signature to discriminate in situ from invasive breast cancer
[11] and a stroma expression signature to predict resistance
to neoadjuvant chemotherapy in breast cancer [10], though
the specific ER+/HER2+ subtype was not specifically evalu-
ated. In normal tissue, colXα1 expression is distinct among
all collagens as it is only expressed in hypertrophic chon-
drocytes [7]. These observations and our data highlight
how colXα1 can be an excellent biomarker for chemoresis-
tance and is a candidate target for specific delivery to ER
+/HER2+ breast tumors. It is not clear why expression of
the COL10A1 gene is such a good marker. In pre-clinical
models, collagens increase multiple tumor properties in-
cluding growth, tumorigenicity, invasion [9, 31], the drug
resistance, and the mesenchymal state [32, 33]. Here, many
related genes and pathways involved in chemoresistance
were correlated with COL10A1 mRNA expression. These
observations further support the development and testing
of colXa1 protein expression as a biomarker, perhaps in
combination with other pathways such as sTILs, EMT
markers. Further study is warranted to determine the func-
tion of colXα1 in mediating resistance.
We were motivated to look at TILs because of the
enrichment of immune pathways, including genes indi-
cative of T cells, in the gene expression data. Several
clinical studies have evaluated TILs as a positive prog-
nostic biomarker in TNBC [2, 34–42]. However, TILs
were not a positive biomarker for luminal subtypes [43].
In this study, TILs were a strong independent predictor in
in ER+/HER2+ subtypes (Table 2, see Additional file 7:
Table S5). In the ER+/HER2+ subtype, TILs and colXα1
both contribute to predict chemosensitivity (Fig. 4, Tables 1
and 2), suggesting that the combination of TILs and
colXα1 IHC score is a strong predictor for ER+/HER+
breast cancers.
This study focused on patients with ER+/HER2+ breast
cancer treated with neoadjuvant chemotherapy and
HER2-targeted therapy and was designed to identify novel
biomarkers predictive of pathologic response. This defin-
ition may have impacted our ability to detect Col10A1 and
TIL association not previously observed in luminal tumors.
The HER2-positive patients generally have a significantly
higher pCR rate in response to NAC+H. However, within
the HER2-positive population, pCR was more common for
ER-negative tumors than for ER- positive tumors [4, 5, 44].
This suggests that for a subset of HER2+ tumors, ER or
a more complex molecular pathway drives response,
and ER+/HER2+ tumors are biologically different than
ER-/HER2+ tumors [45, 46].
Our data represent initial, preliminary evidence that
colXα1 may be a marker for NAC response. The present
study has some limitations, for example, the modest
number of cases could be affected by unknown sample
biases. We have selected cases with similar, but not identi-
cal treatment schedules. Even with a variety of treatment
schedules, TILs and colXα1 have strong predictive power
for chemoresponse suggesting that they are general factors
for NAC responsiveness in ER+/HER2+ breast tumors
and further study of colXα1 and other collagens as pre-
dictive markers is warranted.
Conclusions
In summary, this is the first description, to our knowledge,
of an association between a specific collagen subtype and
response to neoadjuvant chemotherapy in breast cancer.
Although our data cannot confirm causality, the significant
difference in colXα1 expression in the responsive and non-
responsive tumors, are striking. Together with the many
studies showing that collagens, as part of the extracellular
matrix, induce significant differences in the differentiation
and life/death promotion of cancer cells, this study suggests
that stromal expressed colXα1 plays a causative role in the
tumor’s response to therapy. The evaluation of colXα1 pro-
tein levels provides a robust marker in predicting responses
and warrants further evaluation in larger studies.
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